ConductScience.org, home

Paper22754591

Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.

Leung L and 2 others. Ther Adv Med Oncol, 2012. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. Papers, record 22754591. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22754591

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.
PubMed
Journal
Ther Adv Med Oncol
PubMed
Year
2012
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
0.42
iCite
Revised in PubMed
2024-03-18
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Leung LLinda
2Mok TSTony S K
3Loong HHerbert

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119917871American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.J Clin Oncol2009https://conductscience.org/library/papers/19917871PubMed
219494788Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.J Thorac Oncol2009https://conductscience.org/library/papers/19494788PubMed
317167137Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med2006https://conductscience.org/library/papers/17167137PubMed
414701780Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.J Clin Oncol2004https://conductscience.org/library/papers/14701780PubMed
517878479Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.J Clin Oncol2007https://conductscience.org/library/papers/17878479PubMed
616800963Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.Clin Lung Cancer2006https://conductscience.org/library/papers/16800963PubMed
720978446Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.J Thorac Oncol2010https://conductscience.org/library/papers/20978446PubMed
817671148Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.Clin Cancer Res2007https://conductscience.org/library/papers/17671148PubMed
922547605Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.J Clin Oncol2012https://conductscience.org/library/papers/22547605PubMed
1015118073Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med2004https://conductscience.org/library/papers/15118073PubMed
1118678835
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.
J Clin Oncol2008https://conductscience.org/library/papers/18678835PubMed
1219410716Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.Lancet2009https://conductscience.org/library/papers/19410716PubMed
1319692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
1420100966Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.J Clin Oncol2010https://conductscience.org/library/papers/20100966PubMed
1516890793Epidermal growth factor receptor targeting in cancer.Semin Oncol2006https://conductscience.org/library/papers/16890793PubMed
1617442998Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.J Clin Oncol2007https://conductscience.org/library/papers/17442998PubMed
1720573926Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med2010https://conductscience.org/library/papers/20573926PubMed
1811784875Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med2002https://conductscience.org/library/papers/11784875PubMed
1919658185Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.Cancer2009https://conductscience.org/library/papers/19658185PubMed
2016377102Epidermal growth factor receptor (EGFR) signaling in cancer.Gene2006https://conductscience.org/library/papers/16377102PubMed

See all 45 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42488708Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study).MedComm (2020)2026https://conductscience.org/library/papers/42488708PubMed
41413930Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors.Expert Rev Clin Pharmacol2025https://conductscience.org/library/papers/41413930PubMed
39991842Investigation of bioavailability and anti-pancreatic cancer efficacy of a self-nanoemulsifying erlotinib delivery system.Ther Deliv2025https://conductscience.org/library/papers/39991842PubMed
34572386Role of Calcium Homeostasis in Modulating EMT in Cancer.Biomedicines2021https://conductscience.org/library/papers/34572386PubMed
34090412EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.BMC Pulm Med2021https://conductscience.org/library/papers/34090412PubMed
33262410Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.Sci Rep2020https://conductscience.org/library/papers/33262410PubMed
32973931EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer.Ther Adv Med Oncol2020https://conductscience.org/library/papers/32973931PubMed
31572008Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study.Cancer Manag Res2019https://conductscience.org/library/papers/31572008PubMed
30171075RNF144A sustains EGFR signaling to promote EGF-dependent cell proliferation.J Biol Chem2018https://conductscience.org/library/papers/30171075PubMed
29536182Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.Pharm Res2018https://conductscience.org/library/papers/29536182PubMed
26885448Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC).Am J Cancer Res2015https://conductscience.org/library/papers/26885448PubMed
26768483Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Oncologist2016https://conductscience.org/library/papers/26768483PubMed
25538894EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression.Front Oncol2014https://conductscience.org/library/papers/25538894PubMed
25502402Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.Sci Rep2014https://conductscience.org/library/papers/25502402PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22754591

GET https://conductscience.org/api/papers/v1/22754591/references?page=2